Fresenius Kabi Oncology Limited is a premier research organization focused on innovative products in the therapeutic segment of oncology. Our approach to cancer patients, who are the heart of all we do, is to plan one of the broadest portfolios of oncology generic products with a focus on "First To Market" opportunities. We have a well-established Innovation and Development capability, which leads us towards improving the existing treatments for the cancer patients. We also have a highly integrated approach towards product development, regulatory submissions and technology transfers.

The Innovation and Development division at Fresenius Kabi Oncology Limited is well equipped with state-of-the-art equipments and more than 160 scientists. These scientists with their key functional competencies and extensive product experience are engaged in third generation chemotherapeutic research and product development at Fresenius Kabi Oncology Limited.

• Innovative oncology generics
• Novel Drug Delivery Systems
• Clinical Trials and Research